Patients were stratified into 4 risk groups based on recent heart failure hospitalization (HFH) and use of loop diuretics. 1 ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients ...

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite ...

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help ...

Panelists discuss how combination therapies targeting different aspects of spinal muscular atrophy (SMA), such as myostatin ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Panelists discuss how insurance challenges impact spinal muscular atrophy (SMA) care, with prior authorizations becoming more ...